OBJECTIVES: The study aimed to examine the role of patient education about biosimilar medicines, by looking at 1) what kind of information is needed for patients, 2) which information is already available, and 3) how to efficiently reach the patient.

METHODS: This study was performed by means of a systematic literature review, searching in scientific databases (Medline, Embase) and grey literature between November 2019 and January 2020. In addition, public websites of European Patients’ Forum (EPF) members were screened on specific information about biosimilar medicines to bundle relevant information provided by EPF members.

RESULTS: The literature search resulted in 44 scientific articles and four additional articles from other sources. All 75 EPF member associations were screened, of which 13 provided information about biosimilars. Patients mainly have concerns about safety, efficacy, extrapolation of indication, and the societal benefits of biosimilars. Patient education should address these information needs in a consistent and clear manner across resources. Physicians, nurses, pharmacists, patient organizations, and (inter)national competent authorities should therefore join forces when educating patients. Not all patients need the same amount of information, healthcare providers (HCPs) play an important role in addressing these needs. Specific communication strategies for HCPs have already proven to be successful and HCPs should be trained in the proper use of these strategies. EPF members in several disease areas (i.e. rheumatology, gastroenterology, oncology, diabetes) have made efforts in recent years to raise awareness about biosimilars among patients, mainly by providing educational material, toolkits, position papers, and by organizing workshops and seminars.

CONCLUSIONS: In this study, the role of a multistakeholder approach when educating patients about biosimilar medicines was highlighted. Correct and coherent communication from unbiased sources towards patients is in support of national biosimilar policies for a more sustainable healthcare system, from which patients will eventually benefit.